Compounded Semaglutide vs Ozempic and Wegovy: Same Molecule, Very Different Price

If your insurance covers Ozempic or Wegovy, the brand is usually the better choice. It is FDA-approved, it is the product the clinical trials tested, and a covered prescription can cost as little as $25 a month.

If you are paying out of pocket, the picture changes. Wegovy pens start around $199 a month for starting doses under the manufacturer's savings offer and about $349 at maintenance doses, and TrumpRx lists Ozempic and Wegovy at $350, while compounded semaglutide through Arbor starts at a month and does not go up as your dose does.

What you give up with compounded semaglutide is the FDA approval and the direct trial evidence. What you keep is the active ingredient and, with the right program, a physician who adjusts your dose and a pharmacy that prepares it for you. The rest of this article is the detail behind that trade.

Ozempic, Wegovy and compounded semaglutide all contain semaglutide, a GLP-1 receptor agonist that slows stomach emptying, quiets appetite signals and improves how the pancreas releases insulin. That is where the overlap ends.

Ozempic and Wegovy are finished products made by one manufacturer, tested in large trials and approved by the FDA for specific uses. Ozempic is approved for adults with type 2 diabetes, including cardiovascular and kidney risk reduction in that group; weight loss is off-label. Wegovy is approved for chronic weight management, for reducing major cardiovascular events in adults with heart disease and overweight or obesity, and, under accelerated approval, for a form of fatty liver disease with fibrosis.

Compounded semaglutide is prepared by a licensed pharmacy for one patient, on one prescription. The FDA is plain about what that means: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they reach patients.

The results people quote for semaglutide come from the brand products. In the STEP 1 trial, adults with obesity on Wegovy-strength semaglutide 2.4 mg lost 14.9% of body weight on average over 68 weeks, against 2.4% on placebo. The SELECT trial found a 20% lower risk of major cardiovascular events in adults with heart disease and overweight or obesity.

No trial of that size has tested a compounded semaglutide product. When a compounded preparation contains the right form of semaglutide at the stated strength, and is dosed correctly, it contains the same active ingredient the brand does, but no trial has measured how a compounded preparation performs. Quality rests on the pharmacy doing its job, which is why the questions later in this article matter.

Dosing is the other gap. The FDA has received reports of adverse events, some needing hospital care, linked to measuring errors with compounded injectable semaglutide, where patients drew the wrong number of units from a vial. A prefilled pen removes most of that risk; a vial asks you to read a syringe correctly every week.

Scroll the table sideways to see both columns →

During the national shortage, pharmacies had wide room to compound semaglutide. That period is over: the FDA declared the semaglutide shortage resolved on February 21, 2025, and semaglutide is no longer on the shortage list.

What remains is traditional patient-specific compounding under section 503A, where a licensed pharmacy prepares a medication for an individual patient on a prescription. The FDA has said it will treat a compounded product as essentially a copy of a commercially available drug unless there is a documented clinical difference for that patient, and it has proposed excluding semaglutide from the list that lets larger outsourcing facilities compound it from bulk ingredients.

In practice, that puts the weight on the prescriber and the pharmacy. A legitimate program has a licensed physician review your history, document why a compounded preparation fits you, and send the prescription to a licensed pharmacy that prepares it for you by name.

Four questions to ask any provider

• Is the semaglutide the base form used in the approved drugs? The FDA warns that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients and should not be used.
• Which licensed pharmacy prepares it, and is that pharmacy in good standing with its state board?
• What is the concentration in the vial, in milligrams per milliliter, and how many units is my dose?
• Who is my prescribing clinician, and how quickly can I reach them if something feels wrong?

Brand semaglutide got cheaper for cash buyers over the past year. A White House agreement announced in November 2025 set Ozempic and Wegovy at $350 a month through TrumpRx, down from list prices near $1,000 and $1,350. By May 2026, Healthline reported Wegovy pens starting at $199 a month without insurance through the manufacturer's savings offer, the tablet at $149, and higher prices at higher doses.

At Arbor, compounded semaglutide starts at a month with no membership fee, and the price does not change as your dose climbs. Over a year of titration, the flat price matters more than the starting number. Self-pay brand pricing rises at the maintenance doses most people reach.

If your plan covers Ozempic or Wegovy, run that number first. A covered brand prescription can be the cheapest option of all, and it comes with everything the FDA approval carries.

Our clinicians are not choosing between a good product and a bad one. They are matching a patient to the path that fits their coverage, history and budget, and the choice can change. For the medication decision itself, see our framework for choosing a GLP-1 and our semaglutide and tirzepatide comparison.

The brand path makes more sense when

• Your insurance covers Ozempic or Wegovy at a reasonable copay
• You have established heart disease and want the product tested in SELECT
• You would rather use a prefilled pen or a tablet than draw doses from a vial
• You want the regulatory certainty of an FDA-approved product

Compounded semaglutide makes more sense when

• You are paying out of pocket and brand self-pay prices do not fit over a full year
• Your prescriber documents a clinical reason a compounded preparation suits you
• You are comfortable measuring doses from a vial with clear written instructions
• You want flat pricing and ongoing clinician access as your dose changes